William Richard White - 23 Jul 2024 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Financial Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
23 Jul 2024
Net transactions value
-$3,247,425
Form type
4
Filing time
25 Jul 2024, 17:54:02 UTC
Previous filing
18 Jul 2024
Next filing
05 Aug 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $3,504 +500 +1.2% $7.01 42,291 23 Jul 2024 Direct F1
transaction AKRO Common Stock Sale $14,005 -500 -1.2% $28.01 41,791 23 Jul 2024 Direct F1, F2
transaction AKRO Common Stock Options Exercise $974,833 +139,083 +333% $7.01 180,874 24 Jul 2024 Direct F1
transaction AKRO Common Stock Sale $1,592,904 -59,637 -33% $26.71 121,237 24 Jul 2024 Direct F1, F3
transaction AKRO Common Stock Sale $2,160,137 -79,446 -66% $27.19 41,791 24 Jul 2024 Direct F1, F4
transaction AKRO Common Stock Options Exercise $156,104 +22,272 +53% $7.01 64,063 25 Jul 2024 Direct F1
transaction AKRO Common Stock Sale $48,357 -1,791 -2.8% $27.00 62,272 25 Jul 2024 Direct F1, F5
transaction AKRO Common Stock Sale $566,463 -20,481 -33% $27.66 41,791 25 Jul 2024 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -500 -0.26% $0.000000 194,026 23 Jul 2024 Common Stock 500 $7.01 Direct F1, F7
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -139,083 -72% $0.000000 54,943 24 Jul 2024 Common Stock 139,083 $7.01 Direct F1, F7
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -22,272 -41% $0.000000 32,671 25 Jul 2024 Common Stock 22,272 $7.01 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 13, 2024, previously adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.0100 to $28.0101, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2).
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.3500 to $26.9200, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3).
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.9300 to $27.9200, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4).
F5 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.9250 to $27.1200, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5).
F6 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.2100 to $28.1200, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6).
F7 The options are vested and currently exercisable.